Literature DB >> 19837678

Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites.

A Krag1, F Bendtsen, J H Henriksen, S Møller.   

Abstract

OBJECTIVES: Recent studies suggest that cardiac dysfunction precedes development of the hepatorenal syndrome. In this follow-up study, we aimed to investigate the relation between cardiac and renal function in patients with cirrhosis and ascites and the impact of cardiac systolic function on survival. PATIENTS AND
DESIGN: Twenty-four patients with cirrhosis and ascites were included. Cardiac function was investigated by gated myocardial perfusion imaging (MPI) for assessment of cardiac index (CI) and cardiac volumes. The renal function was assessed by determination of glomerular filtration rate (GFR) and renal blood flow (RBF) and the patients were followed up for 12 months.
RESULTS: In patients with a CI below 1.5 l/min/m(2) on MPI, GFR was lower (39 (SD 24) vs 63 (SD 23) ml/min, p = 0.03), RBF was lower (352 (SD 232) vs 561 (SD 229) ml/min, p = 0.06), and serum creatinine was higher (130 (SD 46) vs 78 (SD 29) mumol/l, p<0.01). The number of patients who developed hepatorenal syndrome type 1 within 3 months was higher in the group with low CI than in the high CI group (43% vs 5%, p = 0.04). Patients with the lowest CI (N = 8) had significantly poorer survival at 3, 9, and 12 months compared to those with a higher CI (N = 16), p<0.05. In contrast, the Model for End-stage Liver Disease (MELD) score failed to predict mortality in these patients.
CONCLUSIONS: The development of renal failure and poor outcome in patients with advanced cirrhosis and ascites seem to be related to a cardiac systolic dysfunction. Other parameters may be more important than MELD score to predict prognosis.

Entities:  

Mesh:

Year:  2010        PMID: 19837678     DOI: 10.1136/gut.2009.180570

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  70 in total

1.  Cardiac changes in pediatric liver transplant recipients: are they truly irreversible?

Authors:  Florence Wong
Journal:  Hepatol Int       Date:  2016-02-16       Impact factor: 6.047

Review 2.  Does cirrhotic cardiomyopathy exist? 50 years of uncertainty.

Authors:  Pierpaolo Pellicori; Concetta Torromeo; Angela Calicchia; Alessandra Ruffa; Martina Di Iorio; John G F Cleland; Manuela Merli
Journal:  Clin Res Cardiol       Date:  2013-09-01       Impact factor: 5.460

Review 3.  The Art and Science of Diagnosing and Treating Lung and Heart Disease Secondary to Liver Disease.

Authors:  David S Goldberg; Michael B Fallon
Journal:  Clin Gastroenterol Hepatol       Date:  2015-04-28       Impact factor: 11.382

Review 4.  [Renal insufficiency in patients with hepatic insufficiency].

Authors:  K Lenz; M Binder; R Buder; A Gruber; B Gutschreiter; M Voglmayr
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-26       Impact factor: 0.840

Review 5.  Cirrhotic cardiomyopathy: Implications for the perioperative management of liver transplant patients.

Authors:  Suehana Rahman; Susan V Mallett
Journal:  World J Hepatol       Date:  2015-03-27

Review 6.  Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

Authors:  Hiroshi Fukui
Journal:  World J Hepatol       Date:  2015-03-27

7.  Assessment of diastolic function in the management of patients with cirrhosis.

Authors:  Søren Møller
Journal:  Hepatol Int       Date:  2014-07-27       Impact factor: 6.047

Review 8.  Optimizing medication management for patients with cirrhosis: Evidence-based strategies and their outcomes.

Authors:  Mary J Thomson; Anna S Lok; Elliot B Tapper
Journal:  Liver Int       Date:  2018-06-19       Impact factor: 5.828

9.  Diastolic dysfunction characterizes cirrhotic cardiomyopathy.

Authors:  Piyush O Somani; Qais Contractor; Ajay S Chaurasia; Pravin M Rathi
Journal:  Indian Heart J       Date:  2014-07-23

Review 10.  Kidney-liver pathophysiological crosstalk: its characteristics and importance.

Authors:  Olivia Capalbo; Sofía Giuliani; Alberta Ferrero-Fernández; Paola Casciato; Carlos G Musso
Journal:  Int Urol Nephrol       Date:  2019-09-23       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.